Technical Analysis for OCUP - Ocuphire Pharma, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Resistance | Bearish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Fell Below 50 DMA | Bearish | -5.67% | |
Calm After Storm | Range Contraction | -5.67% | |
Upper Bollinger Band Walk | Strength | -5.67% | |
Weak + Overbought | Other | -5.67% | |
Wide Bands | Range Expansion | -5.67% | |
Overbought Stochastic | Strength | -5.67% | |
Upper Bollinger Band Touch | Strength | -5.67% | |
Gapped Down | Weakness | -5.67% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 12 hours ago |
Down 5% | about 12 hours ago |
Down 3% | about 17 hours ago |
Fell Below Previous Day's Low | about 17 hours ago |
Down 2 % | about 17 hours ago |
Get a Trading Assistant
- Earnings date: 05/13/2024
Ocuphire Pharma, Inc. Description
Ocuphire is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances, pharmacologically-induced mydriasis, and presbyopia. Ocuphire’s second product candidate, APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late stage development, regulatory preparation, and commercialization of drugs in key global markets.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Diabetes Eye Inflammation Ophthalmology Ophthalmic Vascular Disease Vision Diabetic Retinopathy Macular Edema Retina Diabetic Macular Edema Blindness Retinopathy Molecule Product Angiogenesis Night Vision Presbyopia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 6.6 |
52 Week Low | 1.5 |
Average Volume | 241,228 |
200-Day Moving Average | 2.91 |
50-Day Moving Average | 1.95 |
20-Day Moving Average | 1.72 |
10-Day Moving Average | 1.76 |
Average True Range | 0.13 |
RSI (14) | 50.50 |
ADX | 30.47 |
+DI | 27.65 |
-DI | 25.54 |
Chandelier Exit (Long, 3 ATRs) | 1.72 |
Chandelier Exit (Short, 3 ATRs) | 1.89 |
Upper Bollinger Bands | 2.02 |
Lower Bollinger Band | 1.42 |
Percent B (%b) | 0.68 |
BandWidth | 34.91 |
MACD Line | -0.02 |
MACD Signal Line | -0.07 |
MACD Histogram | 0.0544 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.04 | ||||
Resistance 3 (R3) | 2.06 | 2.00 | 2.01 | ||
Resistance 2 (R2) | 2.00 | 1.95 | 2.00 | 1.99 | |
Resistance 1 (R1) | 1.92 | 1.92 | 1.89 | 1.90 | 1.98 |
Pivot Point | 1.86 | 1.86 | 1.85 | 1.86 | 1.86 |
Support 1 (S1) | 1.78 | 1.81 | 1.75 | 1.76 | 1.68 |
Support 2 (S2) | 1.72 | 1.78 | 1.72 | 1.67 | |
Support 3 (S3) | 1.64 | 1.72 | 1.66 | ||
Support 4 (S4) | 1.62 |